SAN FRANCISCO — LifeMine Therapeutics, a biotech informed by the long history of fungi, expects to enter the clinic early next year with a T-cell immunosuppressive and with an antifungal about six months later, CEO Greg Verdine told Endpoints News.
“I’m saying it for the first time that these are the two areas right now that we’re focusing in,” Verdine said in an interview on the sidelines of the annual JP Morgan Healthcare Conference in the Bay Area. The biotech is also working on oncology programs and elsewhere, he noted.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.